US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

17.00

+0.10000.59%

Volume:185.15K

Turnover:3.11M

Market Cap:1.67B

PE:-8.60

High:17.09

Open:17.00

Low:16.55

Close:16.90

52wk High:18.70

52wk Low:4.70

Shares:98.51M

Float Shares:91.33M

Volume Ratio:0.52

T/O Rate:0.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9758

EPS(LYR):-1.5424

ROE:-85.59%

ROA:-33.95%

PB:12.82

PE(LYR):-11.02

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Definium Therapeutics

Exchange:

NASDAQ

Establishment Date:

2019

Employees:

74

Office Location:

One World Trade Center,Suite 8500,New York,New York,United States

Website:

http://www.definiumtx.com

Zip Code:

10007

Phone:

Fax:

- -

Introduction:

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.

Directors

Name

Position

Robert Barrow

Chief Executive Officer and Director

Carol A. Vallone

Chair of the Board

Andreas Krebs

Director

David Gryska

Director

Roger Adsett

Director

Roger Crystal

Director

Suzanne Bruhn

Director

Shareholders

Name

Position

Robert Barrow

Chief Executive Officer and Director

Brandi L. Roberts

Chief Financial Officer and Principal Accounting Officer

Carrie F. Liao

Chief Accounting Officer

Daniel Karlin

Chief Medical Officer

Mark Sullivan

Chief Legal Officer and Corporate Secretary

Matt Wiley

Chief Commercial Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DFTX/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DFTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":17,"timestamp":1770652012002,"preClose":16.9,"halted":0,"volume":185150,"delay":0,"changeRate":0.005917159763313694,"floatShares":91334800,"shares":98509279,"eps":-1.975783,"marketStatus":"Trading","change":0.1,"latestTime":"02-09 10:46:58 EST","open":17,"high":17.09,"low":16.55,"amount":3111049.1587,"amplitude":0.031953,"askPrice":17,"askSize":108,"bidPrice":16.96,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.975783,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":16.9,"preHourTrading":{"tag":"盘前","latestPrice":17.08,"preClose":16.9,"latestTime":"09:29 EST","volume":960,"amount":16040.84832,"timestamp":1770647399922,"change":0.18,"changeRate":0.010651,"amplitude":0.058763},"postHourTrading":{"tag":"盘后","latestPrice":16.9,"preClose":16.9,"latestTime":"19:58 EST","volume":13454,"amount":227299.833,"timestamp":1770425887977,"change":0,"changeRate":0,"amplitude":0.012124},"volumeRatio":0.524779,"impliedVol":0.7003,"impliedVolPercentile":0.0625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","floatShares":91334800,"roa":"-33.95%","roe":"-85.59%","lyrEps":-1.542397,"volumeRatio":0.524779,"shares":98509279,"dividePrice":0,"high":17.09,"amplitude":0.031953,"preClose":16.9,"low":16.55,"week52Low":4.7,"pbRate":"12.82","week52High":18.7,"institutionHeld":0,"latestPrice":17,"committee":0.470588,"eps":-1.975783,"divideRate":0,"volume":185150,"delay":0,"ttmEps":-1.975783,"open":17,"prevYearClose":13.39,"prevWeekClose":16.9,"prevMonthClose":16.88,"prevQuarterClose":13.39,"fiveDayClose":18.23,"twentyDayClose":13.84,"sixtyDayClose":12.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DFTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DFTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.7143,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7143,"analysts":14,"updateTime":1769749200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DFTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DFTX","date":"2026-02-06","current":-8.556102,"percent":0.8,"low":-10.683198,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"high":-8.802064,"avg":-9.819913,"sd":0.530014,"marketCap":1600775783},"quantilePoints":[{"date":"2026-01-16","current":-9.013032,"twenty":-8.970838,"median":-8.907548,"eighty":-8.844258,"marketCap":1515072711},{"date":"2026-01-23","current":-9.944809,"twenty":-9.944809,"median":-9.423248,"eighty":-8.819645,"marketCap":1671702464},{"date":"2026-01-30","current":-10.103035,"twenty":-10.103035,"median":-9.868626,"eighty":-9.013032,"marketCap":1698299969},{"date":"2026-02-06","current":-9.522872,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"marketCap":1600775783}],"updateTime":1770649813640},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":631045282,"yearFounded":2019,"employeeNum":74,"address":"One World Trade Center,Suite 8500,New York,New York,United States","zipCode":"10007","officePhone":"212 220 6633"},"stockCompanyDetail":{"websiteUrl":"http://www.definiumtx.com","stockEarnings":[{"period":"1week","weight":0.0012},{"period":"1month","weight":0.2046},{"period":"3month","weight":0.4444},{"period":"6month","weight":0.7157},{"period":"1year","weight":0.8841},{"period":"ytd","weight":0.2621}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.130491},{"month":2,"riseRate":0.8,"avgChangeRate":0.130328},{"month":3,"riseRate":0.25,"avgChangeRate":0.069329},{"month":4,"riseRate":0.75,"avgChangeRate":0.007711},{"month":5,"riseRate":0.4,"avgChangeRate":-0.002468},{"month":6,"riseRate":0.4,"avgChangeRate":-0.111207},{"month":7,"riseRate":0.8,"avgChangeRate":0.20763},{"month":8,"riseRate":0.2,"avgChangeRate":-0.091548},{"month":9,"riseRate":0.2,"avgChangeRate":-0.174855},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Definium Therapeutics","nameEN":"Definium Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":{"directors":[{"name":"Robert Barrow","position":"Chief Executive Officer and Director"},{"name":"Carol A. Vallone","position":"Chair of the Board"},{"name":"Andreas Krebs","position":"Director"},{"name":"David Gryska","position":"Director"},{"name":"Roger Adsett","position":"Director"},{"name":"Roger Crystal","position":"Director"},{"name":"Suzanne Bruhn","position":"Director"}],"executives":[{"name":"Robert Barrow","position":"Chief Executive Officer and Director"},{"name":"Brandi L. Roberts","position":"Chief Financial Officer and Principal Accounting Officer"},{"name":"Carrie F. Liao","position":"Chief Accounting Officer"},{"name":"Daniel Karlin","position":"Chief Medical Officer"},{"name":"Mark Sullivan","position":"Chief Legal Officer and Corporate Secretary"},{"name":"Matt Wiley","position":"Chief Commercial Officer"}]}}}